

ASX RELEASE

27 August 2025

Results of Annual General Meeting

Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") is pleased to confirm that each of the resolutions put to its Annual General Meeting held earlier today were carried.

Details of the results of the meeting are attached.

This ASX announcement is authorised for release by the Company Secretary.

- End -

About Narmafotinib

Narmafotinib (AMP945) is the company's best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies.

About the ACCENT Trial

The ACCENT trial is entitled '*A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients*'.

The trial is a single-arm open label study conducted in two stages. The first stage (Phase 1b), completed in November 2023, determined an optimal dose of narmafotinib (AMP945) by assessing the safety, tolerability, pharmacokinetics and preliminary efficacy when dosed in combination with gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. The second stage (Phase 2a) of the trial is designed to assess efficacy in combination with gemcitabine and Abraxane. The primary endpoints are Objective Response Rate (ORR) and safety and tolerability, with secondary endpoints including Progression Free Survival (PFS), Overall Survival (OS) and Duration on Trial (DOT).

The trial is being conducted at seven sites in Australia and five sites in South Korea. More information about the ACCENT trial can be found via the ACCENT trial [site](#), the Amplia Therapeutics [website](#) and at ClinicalTrials.gov under the identifier [NCT05355298](#). The Company will provide further updates on the trial as data is accrued.

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:

HACK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [Twitter](#) (@ampliatx) and [LinkedIn](#).

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Remuneration Report	Ordinary	164,466,832 99.12%	231,318 0.14%	1,235,624 0.74%	1,338,076	168,775,430 99.86%	231,318 0.14%	1,338,076	Carried
2 Re-elect Dr Warwick Tong as a Director of the Company	Ordinary	182,768,314 99.32%	15,421 0.01%	1,235,624 0.67%	43,313	187,076,912 99.99%	15,421 0.01%	43,313	Carried
3 Approval of Issues of Equity Securities under Equity Incentive Plan	Ordinary	162,395,631 98.63%	1,017,354 0.62%	1,235,624 0.75%	13,151,704	166,704,229 99.39%	1,017,354 0.61%	13,126,704	Carried
4 Proposed Issue of Options to Dr Warwick Tong (Non-Executive Chairman)	Ordinary	162,078,461 97.22%	3,403,227 2.04%	1,235,624 0.74%	13,276,743	166,387,059 98.00%	3,403,227 2.00%	13,276,743	Carried
5 Proposed Issue of Options to Dr Robert Peach (Non-Executive Director)	Ordinary	162,066,881 97.21%	3,414,807 2.05%	1,235,624 0.74%	9,564,844	166,375,479 97.99%	3,414,807 2.01%	9,564,844	Carried
6 Proposed Issue of Options to Ms Jane Bell (Non-Executive Director)	Ordinary	162,023,461 97.18%	3,443,227 2.07%	1,250,624 0.75%	9,564,844	166,347,059 97.97%	3,443,227 2.03%	9,564,844	Carried
7 Proposed Issue of Zero Exercise Price Options to Dr Christopher Burns (Managing Director and Chief Executive Officer)	Ordinary	161,312,584 96.77%	4,130,329 2.48%	1,250,624 0.75%	13,657,236	165,636,182 97.57%	4,130,329 2.43%	13,657,236	Carried
8 Ratification of issue of Placement Shares under the Placement	Ordinary	99,026,276 97.72%	1,060,151 1.05%	1,250,624 1.23%	55,964,404	103,349,874 98.98%	1,060,151 1.02%	55,964,404	Carried
9 Approval of issue of Shares under the SPP and SPP Shortfall Offer	Ordinary	98,588,661 72.18%	36,676,052 26.85%	1,322,082 0.97%	548,815	103,008,717 73.74%	36,676,052 26.26%	523,815	Carried
10 Approval of proposed issue of Director Placement Shares to Dr Warwick Tong, Non-Executive Chairman	Ordinary	178,642,856 99.07%	387,755 0.22%	1,285,624 0.71%	3,746,437	183,001,454 99.79%	387,755 0.21%	3,746,437	Carried
11 Approval of proposed issue of Director Placement Shares to Dr Christopher Burns, Managing Director and Chief Executive Officer	Ordinary	178,280,718 99.06%	393,175 0.22%	1,285,624 0.72%	4,103,155	182,639,316 99.79%	393,175 0.21%	4,103,155	Carried
12 Approval of proposed issue of Director Placement Shares to Dr Robert Peach, Non-Executive Director	Ordinary	176,783,595 99.01%	416,175 0.23%	1,349,374 0.76%	5,513,528	181,205,943 99.77%	416,175 0.23%	5,513,528	Carried
13 Approval of proposed issue of Director Placement Shares to Ms Jane Bell, Non-Executive Director	Ordinary	178,708,508 99.01%	502,686 0.28%	1,285,624 0.71%	3,565,854	183,067,106 99.73%	502,686 0.27%	3,565,854	Carried
14 Approval for extra 10% Placement Facility	Special	124,703,913 76.11%	37,873,052 23.11%	1,285,624 0.78%	20,200,083	128,752,511 77.13%	38,183,052 22.87%	20,200,083	Carried
15 Approval of Conditional Placement	Ordinary	124,458,775 97.35%	2,099,231 1.64%	1,285,624 1.01%	56,219,042	128,817,373 98.40%	2,099,231 1.60%	56,219,042	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.